Search results
Tumor mutations may not predict response to immunotherapy, study finds
Medical Xpress· 3 days agoThe findings, published in Nature Cancer, upend long-held conventional wisdom and could lead to more effective ways of deciding which patients will benefit most from this type of treatment.
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks· 5 days agoFree Report) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024. The subcutaneous formulation ...
Swiss National Bank Has $3.57 Million Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ETF DAILY NEWS· 6 days agoSwiss National Bank lowered its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 10.2% in the fourth quarter, according to its most recent 13F filing with the ...
Great Lakes Advisors LLC Has $1.11 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ETF DAILY NEWS· 5 days agoGreat Lakes Advisors LLC trimmed its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 50.8% during the fourth quarter, according to its most recent 13F filing with the ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days ago- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00